Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...
Early-onset cancer signature (EOCS): Pan-cancer molecular alterations with prognostic significance in early-onset (EOC) and late-onset (LOC) cancer. Pan-cancer KRAS atlas of 9,056 Chinese patients: ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...
Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight IRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris ...
Comparison of conventional B-cell acute lymphoblastic leukemia (B-ALL) fusion diagnostics (top) and Nanopore-based fusion detection (bottom). Current diagnostics involve multiple tests, whereas ...
The high complexity and diversity of the eukaryotic transcriptome poses significant challenges for the efficient detection of specific transcripts. Conventional targeted RNA-seq methods often require ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results